MET 📈 MetLife - Overview
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US59156R1086
MET: Insurance, Annuities, Employee Benefits, Asset Management
MetLife, Inc. is a multinational financial services company that offers a wide range of insurance, annuities, and asset management services to individuals, corporations, and institutions worldwide. The company's operations are divided into six distinct segments, including Retirement and Income Solutions, Group Benefits, Asia, Latin America, Europe, the Middle East and Africa, and MetLife Holdings, each catering to specific markets and customer needs. Through these segments, MetLife provides an extensive array of products, including life, dental, disability, and accident insurance, as well as annuities, pension products, and investment solutions.
The company's product portfolio is diverse and comprehensive, featuring various types of insurance coverages, such as group short-and long-term disability, individual disability, pet insurance, and accidental death and dismemberment insurance. Additionally, MetLife offers administrative services-only arrangements to employers, general and separate account contracts, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. Its pension risk transfer solutions, institutional income annuities, and structured settlements are designed to help institutions and individuals manage their retirement and financial risks. Furthermore, MetLife provides fixed, indexed-linked, and variable annuities, whole and term life insurance, and longevity reinsurance solutions to address the complex needs of its customers.
MetLife's operations are supported by its global presence, with a significant footprint in key markets across Asia, Latin America, Europe, the Middle East, and Africa. The company's commitment to innovation and customer satisfaction has enabled it to maintain a strong position in the global insurance and financial services industry. With a history dating back to 1999, MetLife, Inc. is headquartered in New York, New York, and is listed on the New York Stock Exchange (NYSE) under the ticker symbol MET. The company's common stock is classified under the GICS Sub Industry: Life & Health Insurance, and its ISIN is US59156R1086. For more information, investors and customers can visit the company's website at https://www.metlife.com.
Additional Sources for MET Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
MET Stock Overview
Market Cap in USD | 57,464m |
Sector | Financial Services |
Industry | Insurance - Life |
GiC Sub-Industry | Life & Health Insurance |
IPO / Inception | 2000-04-05 |
MET Stock Ratings
Growth 5y | 71.5% |
Fundamental | 35.1% |
Dividend | 43.0% |
Rel. Strength Industry | -13 |
Analysts | 4.2/5 |
Fair Price Momentum | 86.53 USD |
Fair Price DCF | 552.46 USD |
MET Dividends
Dividend Yield 12m | 2.67% |
Yield on Cost 5y | 5.06% |
Annual Growth 5y | 3.43% |
Payout Consistency | 32.0% |
MET Growth Ratios
Growth Correlation 3m | 15% |
Growth Correlation 12m | 88.1% |
Growth Correlation 5y | 85.4% |
CAGR 5y | 13.63% |
CAGR/Mean DD 5y | 1.22 |
Sharpe Ratio 12m | 1.02 |
Alpha | -4.02 |
Beta | 1.25 |
Volatility | 34.36% |
Current Volume | 8296.5k |
Average Volume 20d | 3898.3k |
As of December 21, 2024, the stock is trading at USD 81.36 with a total of 8,296,509 shares traded.
Over the past week, the price has changed by -1.96%, over one month by -1.50%, over three months by +1.34% and over the past year by +28.66%.
Partly, yes. Based on ValueRay Fundamental Analyses, MetLife (NYSE:MET) is currently (December 2024) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 35.07 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of MET as of December 2024 is 86.53. This means that MET is currently overvalued and has a potential downside of 6.35%.
MetLife has received a consensus analysts rating of 4.20. Therefor, it is recommend to buy MET.
- Strong Buy: 7
- Buy: 5
- Hold: 2
- Sell: 1
- Strong Sell: 0
According to ValueRays Forecast Model, MET MetLife will be worth about 95 in December 2025. The stock is currently trading at 81.36. This means that the stock has a potential upside of +16.79%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 92.5 | 13.7% |
Analysts Target Price | 78.5 | -3.5% |
ValueRay Target Price | 95 | 16.8% |